Lysosomal Abnormalities in Cardiovascular Disease
Abstract
:1. Introduction
2. Lysosome Dysfunction and Cardiovascular Diseases
3. Phenotypes of Danon Cardiomyopathy
4. Defective Autophagy Correlates to Danon Cardiomyopathy
5. Deficiency of the B Isoform of LAMP-2 is the Main Causative Factor of Danon Cardiomyopathy
6. A Novel Mechanism of LAMP-2B in Autophagosome-Lysosome Fusion in CMs
7. Gene Therapy to Treat LSDs
8. Perspectives
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
LSDs | Lysosomal storage disorders |
GAA | Acid α-glucosidase |
LAMP-2 | Lysosomal associated membrane protein-2 |
a-Gal A | Alpha-galactosidase A |
Gb3 | Globotriaosylceramide |
MPS | Mucopolysaccharidosis |
GAGs | Glycosaminoglycans |
TFEB | Transcription factor EB |
CM | Cardiomyocyte |
I/R | Ischemia-reperfusion |
ECM | Extracellular matrix |
DCM | Dilated cardiomyopathy |
CHF | Congestive heart failure |
V-ATPase | Vacuolar-type H+-ATPase |
CMA | Chaperone mediated autophagy |
RCAN1 | Calcineurin |
RYR2 | Ryanodine receptor 2 |
MEF2D | Myocyte enhancer factor 2D |
WT | Wildtype |
hiPSC-CMs | Cardiomyocytes derived from human induced pluripotent stem cells |
ROS | Reactive oxygen species |
KO | Knockout |
Mitophagy | Mitochondrial autophagy |
S-OPA1 | Short isoform of optic atrophy 1 |
LC3 | Microtubule-associated protein light chain 3 |
MEFs | Mouse embryonic fibroblasts |
STX17 | Syntaxin 17 |
SNAP29 | Synaptosome-associated protein 29 |
VAMP8 | Vesicle-associated membrane protein 8 |
ATG14 | Autophagy related 14 |
IDUA | α-L-iduronidase |
AAV9 | Adeno-associated virus serotype 9 |
FDA | Food and Drug Administration |
References
- Settembre, C.; Fraldi, A.; Medina, D.L.; Ballabio, A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell. Biol. 2013, 14, 283–296. [Google Scholar] [CrossRef] [Green Version]
- Ballabio, A.; Gieselmann, V. Lysosomal disorders: From storage to cellular damage. Biochim. Biophys. Acta 2009, 1793, 684–696. [Google Scholar] [CrossRef] [Green Version]
- Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiuve, S.E.; Cushman, M.; Delling, F.N.; Deo, R.; et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018, 137, e67–e492. [Google Scholar] [CrossRef]
- Wang, X.; Robbins, J. Proteasomal and lysosomal protein degradation and heart disease. J. Mol. Cell. Cardiol. 2014, 71, 16–24. [Google Scholar] [CrossRef] [Green Version]
- Perera, R.M.; Zoncu, R. The Lysosome as a Regulatory Hub. Annu. Rev. Cell. Dev. Biol. 2016, 32, 223–253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lawrence, R.E.; Zoncu, R. The lysosome as a cellular centre for signalling, metabolism and quality control. Nat. Cell. Biol. 2019, 21, 133–142. [Google Scholar] [CrossRef] [PubMed]
- Winchester, B.; Vellodi, A.; Young, E. The molecular basis of lysosomal storage diseases and their treatment. Biochem. Soc. Trans. 2000, 28, 150–154. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leslie, N.; Bailey, L. Pompe Disease. In GeneReviews; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
- Chi, C.; Leonard, A.; Knight, W.E.; Beussman, K.M.; Zhao, Y.; Cao, Y.; Londono, P.; Aune, E.; Trembley, M.A.; Small, E.M.; et al. LAMP-2B regulates human cardiomyocyte function by mediating autophagosome-lysosome fusion. Proc. Natl. Acad. Sci. USA 2019, 116, 556–565. [Google Scholar] [CrossRef] [Green Version]
- Di Mauro, S.; Tanji, K.; Hirano, M. LAMP-2 deficiency (Danon disease). Acta Myol. 2007, 26, 79–82. [Google Scholar]
- Karen, J.K.; Hale, E.K.; Ma, L. Angiokeratoma corporis diffusum (Fabry disease). Dermatol. Online J. 2005, 11, 8. [Google Scholar]
- Braunlin, E.A.; Harmatz, P.R.; Scarpa, M.; Furlanetto, B.; Kampmann, C.; Loehr, J.P.; Ponder, K.P.; Roberts, W.C.; Rosenfeld, H.M.; Giugliani, R. Cardiac disease in patients with mucopolysaccharidosis: Presentation, diagnosis and management. J. Inherit. Metab. Dis. 2011, 34, 1183–1197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sardiello, M.; Palmieri, M.; di Ronza, A.; Medina, D.L.; Valenza, M.; Gennarino, V.A.; Di Malta, C.; Donaudy, F.; Embrione, V.; Polishchuk, R.S.; et al. A gene network regulating lysosomal biogenesis and function. Science 2009, 325, 473–477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Settembre, C.; Di Malta, C.; Polito, V.A.; Garcia Arencibia, M.; Vetrini, F.; Erdin, S.; Erdin, S.U.; Huynh, T.; Medina, D.; Colella, P.; et al. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332, 1429–1433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanbe, A.; Osinska, H.; Saffitz, J.E.; Glabe, C.G.; Kayed, R.; Maloyan, A.; Robbins, J. Desmin-related cardiomyopathy in transgenic mice: A cardiac amyloidosis. Proc. Natl. Acad. Sci. USA 2004, 101, 10132–10136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weekes, J.; Morrison, K.; Mullen, A.; Wait, R.; Barton, P.; Dunn, M.J. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003, 3, 208–216. [Google Scholar] [CrossRef]
- Pan, B.; Zhang, H.; Cui, T.; Wang, X. TFEB activation protects against cardiac proteotoxicity via increasing autophagic flux. J. Mol. Cell Cardiol. 2017, 113, 51–62. [Google Scholar] [CrossRef]
- Ma, X.; Godar, R.J.; Liu, H.; Diwan, A. Enhancing lysosome biogenesis attenuates BNIP3-induced cardiomyocyte death. Autophagy 2012, 8, 297–309. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Xiang, X.; Xu, Z. Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB). Biotechnol. Appl. Biochem. 2019, 66, 555–563. [Google Scholar] [CrossRef]
- Lutgens, S.P.; Cleutjens, K.B.; Daemen, M.J.; Heeneman, S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007, 21, 3029–3041. [Google Scholar] [CrossRef]
- Blondelle, J.; Lange, S.; Greenberg, B.H.; Cowling, R.T. Cathepsins in heart disease-chewing on the heartache? Am. J. Physiol. Heart Circ. Physiol. 2015, 308, H974–H976. [Google Scholar] [CrossRef] [Green Version]
- Cheng, X.W.; Obata, K.; Kuzuya, M.; Izawa, H.; Nakamura, K.; Asai, E.; Nagasaka, T.; Saka, M.; Kimata, T.; Noda, A.; et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006, 48, 979–987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naseem, R.H.; Hedegard, W.; Henry, T.D.; Lessard, J.; Sutter, K.; Katz, S.A. Plasma cathepsin D isoforms and their active metabolites increase after myocardial infarction and contribute to plasma renin activity. Basic Res. Cardiol. 2005, 100, 139–146. [Google Scholar] [CrossRef] [PubMed]
- Wuopio, J.; Hilden, J.; Bring, C.; Kastrup, J.; Sajadieh, A.; Jensen, G.B.; Kjoller, E.; Kolmos, H.J.; Larsson, A.; Jakobsen, J.C.; et al. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: A CLARICOR trial sub-study. Atherosclerosis 2018, 278, 97–102. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez, E.A.; Martins, G.R.; Tavares, A.M.V.; Viegas, M.; Poletto, E.; Giugliani, R.; Matte, U.; Baldo, G. Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I mice. Life Sci. 2018, 196, 102–109. [Google Scholar] [CrossRef] [PubMed]
- Agudelo, D.; Bourassa, P.; Berube, G.; Tajmir-Riahi, H.A. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity. J. Photochem. Photobiol. B 2016, 158, 274–279. [Google Scholar] [CrossRef] [PubMed]
- Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J.S. Doxorubicin cardiomyopathy. Cardiology 2010, 115, 155–162. [Google Scholar] [CrossRef] [PubMed]
- Li, D.L.; Wang, Z.V.; Ding, G.; Tan, W.; Luo, X.; Criollo, A.; Xie, M.; Jiang, N.; May, H.; Kyrychenko, V.; et al. Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification. Circulation 2016, 133, 1668–1687. [Google Scholar] [CrossRef] [Green Version]
- Nishino, I.; Fu, J.; Tanji, K.; Yamada, T.; Shimojo, S.; Koori, T.; Mora, M.; Riggs, J.E.; Oh, S.J.; Koga, Y.; et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000, 406, 906–910. [Google Scholar] [CrossRef]
- D’Souza, R.S.; Levandowski, C.; Slavov, D.; Graw, S.L.; Allen, L.A.; Adler, E.; Mestroni, L.; Taylor, M.R. Danon disease: Clinical features, evaluation, and management. Circ. Heart Fail. 2014, 7, 843–849. [Google Scholar] [CrossRef] [Green Version]
- Yoshida, S.; Nakanishi, C.; Okada, H.; Mori, M.; Yokawa, J.; Yoshimuta, T.; Ohta, K.; Konno, T.; Fujino, N.; Kawashiri, M.A.; et al. Characteristics of induced pluripotent stem cells from clinically divergent female monozygotic twins with Danon disease. J. Mol. Cell Cardiol. 2018, 114, 234–242. [Google Scholar] [CrossRef]
- Panning, B. X-chromosome inactivation: The molecular basis of silencing. J. Biol. 2008, 7, 30. [Google Scholar] [CrossRef] [PubMed]
- Ng, K.M.; Mok, P.Y.; Butler, A.W.; Ho, J.C.; Choi, S.W.; Lee, Y.K.; Lai, W.H.; Au, K.W.; Lau, Y.M.; Wong, L.Y.; et al. Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor. Circulation 2016, 134, 1373–1389. [Google Scholar] [CrossRef] [PubMed]
- Hashem, S.I.; Perry, C.N.; Bauer, M.; Han, S.; Clegg, S.D.; Ouyang, K.; Deacon, D.C.; Spinharney, M.; Panopoulos, A.D.; Izpisua Belmonte, J.C.; et al. Brief Report: Oxidative Stress Mediates Cardiomyocyte Apoptosis in a Human Model of Danon Disease and Heart Failure. Stem Cells 2015, 33, 2343–2350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oku, M.; Sakai, Y. Three Distinct Types of Microautophagy Based on Membrane Dynamics and Molecular Machineries. Bioessays 2018, 40, e1800008. [Google Scholar] [CrossRef]
- Li, W.W.; Li, J.; Bao, J.K. Microautophagy: Lesser-known self-eating. Cell. Mol. Life Sci. 2012, 69, 1125–1136. [Google Scholar] [CrossRef]
- Kaushik, S.; Cuervo, A.M. The coming of age of chaperone-mediated autophagy. Nat. Rev. Mol. Cell Biol. 2018, 19, 365–381. [Google Scholar] [CrossRef]
- Alfaro, I.E.; Albornoz, A.; Molina, A.; Moreno, J.; Cordero, K.; Criollo, A.; Budini, M. Chaperone Mediated Autophagy in the Crosstalk of Neurodegenerative Diseases and Metabolic Disorders. Front. Endocrinol. (Lausanne) 2018, 9, 778. [Google Scholar] [CrossRef]
- Liu, H.; Wang, P.; Song, W.; Sun, X. Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways. FASEB J. 2009, 23, 3383–3392. [Google Scholar] [CrossRef]
- Belevych, A.E.; Radwanski, P.B.; Carnes, C.A.; Gyorke, S. ’Ryanopathy’: Causes and manifestations of RyR2 dysfunction in heart failure. Cardiovasc. Res. 2013, 98, 240–247. [Google Scholar] [CrossRef] [Green Version]
- Yang, Q.; She, H.; Gearing, M.; Colla, E.; Lee, M.; Shacka, J.J.; Mao, Z. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009, 323, 124–127. [Google Scholar] [CrossRef] [Green Version]
- Gottlieb, R.A.; Mentzer, R.M., Jr. Autophagy: An affair of the heart. Heart Fail. Rev. 2013, 18, 575–584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sciarretta, S.; Maejima, Y.; Zablocki, D.; Sadoshima, J. The Role of Autophagy in the Heart. Annu. Rev. Physiol. 2018, 80, 1–26. [Google Scholar] [CrossRef] [PubMed]
- Mizushima, N. Autophagy: Process and function. Genes Dev. 2007, 21, 2861–2873. [Google Scholar] [CrossRef] [Green Version]
- Banerjee, I.; Fuseler, J.W.; Price, R.L.; Borg, T.K.; Baudino, T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H1883–H1891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, F. Autophagy in vascular endothelial cells. Clin. Exp. Pharmacol. Physiol. 2016, 43, 1021–1028. [Google Scholar] [CrossRef]
- Kikuchi, K.; Poss, K.D. Cardiac regenerative capacity and mechanisms. Annu. Rev. Cell Dev. Biol. 2012, 28, 719–741. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Ying, Z.; Bosy-Westphal, A.; Zhang, J.; Schautz, B.; Later, W.; Heymsfield, S.B.; Muller, M.J. Specific metabolic rates of major organs and tissues across adulthood: Evaluation by mechanistic model of resting energy expenditure. Am. J. Clin. Nutr. 2010, 92, 1369–1377. [Google Scholar] [CrossRef]
- Doenst, T.; Nguyen, T.D.; Abel, E.D. Cardiac metabolism in heart failure: Implications beyond ATP production. Circ. Res. 2013, 113, 709–724. [Google Scholar] [CrossRef] [Green Version]
- Reichelt, M.E.; Mellor, K.M.; Curl, C.L.; Stapleton, D.; Delbridge, L.M. Myocardial glycophagy—A specific glycogen handling response to metabolic stress is accentuated in the female heart. J. Mol. Cell. Cardiol. 2013, 65, 67–75. [Google Scholar] [CrossRef] [Green Version]
- Danon, M.J.; Oh, S.J.; DiMauro, S.; Manaligod, J.R.; Eastwood, A.; Naidu, S.; Schliselfeld, L.H. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981, 31, 51–57. [Google Scholar] [CrossRef]
- Nascimbeni, A.C.; Fanin, M.; Angelini, C.; Sandri, M. Autophagy dysregulation in Danon disease. Cell Death Dis. 2017, 8, e2565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Twig, G.; Shirihai, O.S. The interplay between mitochondrial dynamics and mitophagy. Antioxid Redox Signal. 2011, 14, 1939–1951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wai, T.; Garcia-Prieto, J.; Baker, M.J.; Merkwirth, C.; Benit, P.; Rustin, P.; Ruperez, F.J.; Barbas, C.; Ibanez, B.; Langer, T. Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science 2015, 350, aad0116. [Google Scholar] [CrossRef] [PubMed]
- Beussman, K.M.; Rodriguez, M.L.; Leonard, A.; Taparia, N.; Thompson, C.R.; Sniadecki, N.J. Micropost arrays for measuring stem cell-derived cardiomyocyte contractility. Methods 2016, 94, 43–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perez, L.; McLetchie, S.; Gardiner, G.J.; Deffit, S.N.; Zhou, D.; Blum, J.S. LAMP-2C Inhibits MHC Class II Presentation of Cytoplasmic Antigens by Disrupting Chaperone-Mediated Autophagy. J. Immunol. 2016, 196, 2457–2465. [Google Scholar] [CrossRef] [Green Version]
- Cuervo, A.M.; Dice, J.F. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 1996, 273, 501–503. [Google Scholar] [CrossRef]
- Massey, A.C.; Kaushik, S.; Sovak, G.; Kiffin, R.; Cuervo, A.M. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl. Acad. Sci. USA 2006, 103, 5805–5810. [Google Scholar] [CrossRef] [Green Version]
- Fujiwara, Y.; Furuta, A.; Kikuchi, H.; Aizawa, S.; Hatanaka, Y.; Konya, C.; Uchida, K.; Yoshimura, A.; Tamai, Y.; Wada, K.; et al. Discovery of a novel type of autophagy targeting RNA. Autophagy 2013, 9, 403–409. [Google Scholar] [CrossRef] [Green Version]
- Fujiwara, Y.; Kikuchi, H.; Aizawa, S.; Furuta, A.; Hatanaka, Y.; Konya, C.; Uchida, K.; Wada, K.; Kabuta, T. Direct uptake and degradation of DNA by lysosomes. Autophagy 2013, 9, 1167–1171. [Google Scholar] [CrossRef] [Green Version]
- Lee, Y.K.; Lee, J.A. Role of the mammalian ATG8/LC3 family in autophagy: Differential and compensatory roles in the spatiotemporal regulation of autophagy. BMB Rep. 2016, 49, 424–430. [Google Scholar] [CrossRef] [Green Version]
- Itakura, E.; Kishi-Itakura, C.; Mizushima, N. The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell 2012, 151, 1256–1269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diao, J.; Liu, R.; Rong, Y.; Zhao, M.; Zhang, J.; Lai, Y.; Zhou, Q.; Wilz, L.M.; Li, J.; Vivona, S.; et al. ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. Nature 2015, 520, 563–566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Friedmann, T. A brief history of gene therapy. Nat. Genet. 1992, 2, 93–98. [Google Scholar] [CrossRef] [PubMed]
- Escors, D.; Breckpot, K. Lentiviral vectors in gene therapy: Their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz) 2010, 58, 107–119. [Google Scholar] [CrossRef] [Green Version]
- Sibbald, B. Death but one unintended consequence of gene-therapy trial. CMAJ 2001, 164, 1612. [Google Scholar]
- Anguela, X.M.; High, K.A. Entering the Modern Era of Gene Therapy. Annu. Rev. Med. 2019, 70, 273–288. [Google Scholar] [CrossRef] [Green Version]
- Srivastava, A. In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 2016, 21, 75–80. [Google Scholar] [CrossRef] [Green Version]
- Wang, D.; Tai, P.W.L.; Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019, 18, 358–378. [Google Scholar] [CrossRef]
- Chandler, R.J.; LaFave, M.C.; Varshney, G.K.; Trivedi, N.S.; Carrillo-Carrasco, N.; Senac, J.S.; Wu, W.; Hoffmann, V.; Elkahloun, A.G.; Burgess, S.M.; et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Investig. 2015, 125, 870–880. [Google Scholar] [CrossRef] [Green Version]
- Donsante, A.; Miller, D.G.; Li, Y.; Vogler, C.; Brunt, E.M.; Russell, D.W.; Sands, M.S. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317, 477. [Google Scholar] [CrossRef] [Green Version]
- Colella, P.; Ronzitti, G.; Mingozzi, F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. Methods Clin. Dev. 2018, 8, 87–104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beck, M. Treatment strategies for lysosomal storage disorders. Dev. Med. Child. Neurol. 2018, 60, 13–18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fukushima, M.; Inoue, T.; Miyai, T.; Obata, R. Retinal dystrophy associated with Danon disease and pathogenic mechanism through LAMP2-mutated retinal pigment epithelium. Eur. J. Ophthalmol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Konecki, D.S.; Foetisch, K.; Zimmer, K.P.; Schlotter, M.; Lichter-Konecki, U. An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Biochem. Biophys. Res. Commun. 1995, 215, 757–767. [Google Scholar] [CrossRef]
Lysosome Function | Lysosomal Component/Pathway | Disease/Models | References |
---|---|---|---|
Insufficient | V-ATPase/lysosome acidification | Doxorubicin-induced cardiotoxicity | [28] |
TFEB/biogenesis | cardiac proteinopathy/desmin-related cardiomyopathy | [17] | |
LAMP-2B/autophagy | Danon disease | [9] | |
TFEB/biogenesis | Myocardial I/R injury | [19] | |
Excessive | Cathepsin B | Coronary heart disease (CLARICOR trial) | [24] |
Cathepsin B | Mucopolysaccharidosis type I | [25] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chi, C.; Riching, A.S.; Song, K. Lysosomal Abnormalities in Cardiovascular Disease. Int. J. Mol. Sci. 2020, 21, 811. https://doi.org/10.3390/ijms21030811
Chi C, Riching AS, Song K. Lysosomal Abnormalities in Cardiovascular Disease. International Journal of Molecular Sciences. 2020; 21(3):811. https://doi.org/10.3390/ijms21030811
Chicago/Turabian StyleChi, Congwu, Andrew S. Riching, and Kunhua Song. 2020. "Lysosomal Abnormalities in Cardiovascular Disease" International Journal of Molecular Sciences 21, no. 3: 811. https://doi.org/10.3390/ijms21030811